SDGR

Schrodinger Inc
NASDAQHEALTHCAREHEALTH INFORMATION SERVICES

Key Statistics

Market Cap
$1.30B
P/E Ratio
EPS
$-0.72
Beta
1.66
52W High
$23.02
52W Low
$10.95
50-Day MA
$15.96
200-Day MA
$15.07
Dividend Yield
Profit Margin
-21.00%
Forward P/E
PEG Ratio

About Schrodinger Inc

Schrdinger, Inc. provides a physics-based software platform that enables the discovery of novel molecules for drug development and material applications. The company is headquartered in New York, New York.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$259.04M
Gross Profit (TTM)$147.31M
EBITDA$-147.58M
Operating Margin-70.60%
Return on Equity-16.20%
Return on Assets-14.40%
Revenue/Share (TTM)$3.50
Book Value$4.21
Price-to-Book4.00
Price-to-Sales (TTM)5.02
EV/Revenue3.897
EV/EBITDA-10.82
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)7.50%
Shares Outstanding$65.64M
Float$57.33M
% Insiders3.00%
% Institutions96.61%

Historical Volatility

HV 10-Day
57.78%
HV 20-Day
42.75%
HV 30-Day
43.19%
HV 60-Day
54.28%
HV Rank
23.4%

Volatility is currently expanding

Analyst Ratings

Consensus ($21.43 target)
5
Buy
2
Hold

Latest News

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement t.

Business Wire8/14/2026Neutral
Schrodinger Q2 Earnings Call Highlights

Schrodinger NASDAQ: SDGR said second-quarter annual contract value growth accelerated as demand broadened across large pharmaceutical customers, biotechnology companies and materials-science customers, while the company launched early access for Bunsen, its agentic AI co-scientist.

MarketBeat8/6/2026Neutral
Schrodinger: A Rare AI-Adjacent Disruptor Still Not Priced For It

Schrödinger is challenging the incumbent drug-trial method—physics-simulated molecular design that cuts the cost, time, and animal testing of building and screening thousands of candidates. The current EV is roughly accounted for by the software leg alone - the royalties business and the disruption TAM are barely priced in, if at all. Three drivers - a regulatory push away from animal testing, AI-led consumption growth, and Bunsen - open up asymmetric upside that is not required for the base case.

Seeking Alpha8/4/2026Neutral
Schrödinger to Announce Second Quarter 2026 Financial Results on August 5

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform,.

Business Wire7/22/2026Neutral
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on July 16, 2026, the company granted restricted stock units (RSUs) with respect to 3,691 shares of the company's common stock to four newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to.

Business Wire7/20/2026Neutral
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on June 12, 2026, the company granted restricted stock units (RSUs) with respect to 10,771 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement.

Business Wire6/18/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SDGR and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 8/18/2026